Medical treatment involving investigational drugs and genetic profile of thymic carcinoma

Lung Cancer

Volumn 93, Issue , 2016, Pages 77-81

  Asao, Tetsuhiko ^a,b   Fujiwara, Yutaka ^a   Sunami, Kuniko ^a   Kitahara, Shinsuke ^a   Goto, Yasushi ^a   Kanda, Shintaro ^a   Horinouchi, Hidehito ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Ichikawa, Hitoshi ^c   Kohno, Takashi ^c   Tsuta, Koji ^a,d   Watanabe, Shun ichi ^a   Takahashi, Kazuhisa ^b   Ohe, Yuichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Genetic profile; Investigational drugs; Next generation sequencing; Thymic carcinoma

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; NEW DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DRUG EFFICACY; FBXW7 GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAL RECORD REVIEW; NEXT GENERATION SEQUENCING; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THYMUS CANCER; TREATMENT RESPONSE; CANCER STAGING; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; THYMUS NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RETROSPECTIVE STUDIES; THYMUS NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959387489     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.01.004     Document Type: Article

References (29)

1. Engels E.A., Pfeiffer R.M. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int. J. Cancer 2003, 105:546-551.
2. Kondo K., Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann. Thorac. Surg. 2003, 76:878-884. discussion 884-875.
3. Falkson C.B., Bezjak A., Darling G., et al. The management of thymoma: a systematic review and practice guideline. J. Thorac. Oncol. 2009, 4:911-919.
4. Ahmad U., Yao X., Detterbeck F., et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J. Thorac. Cardiovasc. Surg. 2015, 149:95-100. 101.e101-102.
5. Loehrer P.J., Kim K., Aisner S.C., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group Southwest Oncology Group, and Southeastern Cancer Study Group. J. Clin. Oncol. 1994, 12:1164-1168.
6. Agatsuma T., Koizumi T., Kanda S., et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J. Thorac. Oncol. 2011, 6:2130-2134.
7. Furugen M., Sekine I., Tsuta K., et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn. J. Clin. Oncol. 2011, 41:1013-1016.
8. Lemma G.L., Lee J.W., Aisner S.C., et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J. Clin. Oncol. 2011, 29:2060-2065.
9. Hirai F., Yamanaka T., Taguchi K., et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann. Oncol. 2015, 26:363-368.
10. Ströbel P., Hartmann M., Jakob A., et al. Thymic carcinoma with overexpression of mutated KIT and the response to Imatinib. N. Engl. J. Med. 2004, 350:2625-2626.
11. Thomas A., Rajan A., Berman A., et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015, 16:177-186.
12. Girard N., Shen R., Guo T., et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin. Cancer Res. 2009, 15:6790-6799.
13. Shitara M., Okuda K., Suzuki A., et al. Genetic profiling of thymic carcinoma using targeted next-generation sequencing. Lung Cancer 2014, 86:174-179.
14. Wang Y., Thomas A., Lau C., et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci. Rep. 2014, 4:7336.
15. Moreira A.L., Won H.H., McMillan R., et al. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. J. Thorac. Oncol 2015, 10:373-380.
16. Masaoka A. Staging system of thymoma. J. Thorac. Oncol. 2010, 5(10 Suppl. 4):S304-S312.
17. Zhang L., Chen L., Sah S., et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist 2014, 19:336-343.
18. Fujisaka Y., Horiike A., Shimizu T., et al. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Jpn. J. Clin. Oncol. 2006, 36:768-774.
19. Shimizu T., Yamamoto N., Yamada Y., et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother. Pharmacol. 2008, 61:751-758.
20. Yamamoto N., Tamura T., Yamamoto N., et al. Phase I dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2009, 64:1165-1172.
21. Kuenen B., Witteveen P.O., Ruijter R., et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin. Cancer Res. 2010, 16:1915-1923.
22. Kurzrock R., Sherman S.I., Ball D.W., et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 2011, 29:2660-2666.
23. Murakami H., Ueda Y., Shimoyama T., et al. Phase I pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother. Pharmacol. 2011, 67:1119-1128.
24. Yamada K., Yamamoto N., Yamada Y., et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:2528-2537.
25. Asahina H., Tamura Y., Nokihara H., et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother. Pharmacol. 2012, 69:1477-1486.
26. Nokihara H., Yamamoto N., Yamada Y., et al. A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother. Pharmacol. 2012, 70:559-565.
27. Seki Y., Yamamoto N., Tamura Y., et al. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 69:1099-1105.
28. Yamamoto N., Nokihara H., Yamada Y., et al. A Phase I dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012, 103:504-509.
29. Yamamoto N., Nokihara H., Yamada Y., et al. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71:1645-1655.